The Scorecard: AEHR Sell — Correct so far

This is a Scorecard review, revisiting a past LF0 research call against what actually happened.

Ticker: AEHR Rating: Sell Published: 2026-06-18 Entry price: $115.30 Latest price: $95.59 as of 2026-08-25 Stock return since entry: -17.1% Signal return: +17.1% Verdict: Correct so far

This call is still open — LF0 tracks every directional call for 182 days from publication, then freezes the verdict permanently. This one’s tracking window closes 2026-12-17.

Read the original LF0 analysis

What I Said

I argued that AEHR’s product differentiation and cash position were not enough to offset the weak operating picture. My focus was on the sharp year-over-year revenue decline, deeply negative margins, ongoing cash burn, and a valuation that left little margin for error. In other words, I thought the stock still had too much fundamental risk embedded in it for a Sell call to be comfortable.

Peer Comparison

Why It’s Working (Or Not)

So far, that bearish call has worked: if I had shorted AEHR at my entry price, I would be up about 17.1% as the stock has fallen since I published it. The peer set has also been broadly weak, with most of the comparable semiconductor names down over the same stretch, so AEHR’s decline has fit a tougher industry backdrop rather than standing out as an isolated move. What matters for my original thesis is that the weak fundamentals I highlighted have not been disproven by the price action; instead, the market has continued to treat AEHR as a name with limited room for execution error. I still cannot claim the thesis is fully validated on fundamentals alone, because I have not shown improvement in revenue, EBITDA, or cash generation—only that the short side has been rewarded so far.

What Could Still Prove Me Wrong

I would be wrong if AEHR starts showing sustained improvement in the exact areas I flagged: revenue growth stabilizing, EBITDA moving meaningfully toward breakeven, and cash burn easing rather than persisting. If the company can demonstrate that the margin structure is improving and that execution risk is falling, the valuation argument behind my Sell call would weaken materially. A rebound in the stock alone would not be enough to disprove me; what would matter is a real turn in the operating metrics that originally made the risk-reward look unfavorable.

The June 2026 Cohort

Other directional calls published the same month:

Live LF0 scorecard: The Scorecard | Research Performance dashboard

Past performance does not guarantee future results. Nothing here is investment advice or a recommendation to buy or sell securities. Returns use LF0’s daily-close scorecard methodology.